UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 22, 2010
ONCOGENEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 033-80623 | | 95-4343413 |
| (State or other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
1522 217th Place S.E.
Bothell, Washington
| | 98021 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(425) 686-1500
| |
N/A
|
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 8.01 Other Events.
On September 22, 2010, OncoGenex Pharmaceuticals, Inc. issued a press release entitled “OncoGenex Pharmaceuticals, Inc. - - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial.” A copy of the press release is filed as Exhibit 99.1 and incorporated herein by reference.
Exhibit 99.1 to this Form 8-K shall be deemed “filed” and not furnished for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| | | |
| Exhibit Number | | Description |
| 99.1 | | Press Release of OncoGenex Pharmaceuticals, Inc. dated September 22, 2010 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | |
| | | ONCOGENEX PHARMACEUTICALS, INC. |
| Date: October 14, 2010 | | /s/ Cameron Lawrence |
| | | Cameron Lawrence
Principal Financial Officer |
3
EXHIBIT INDEX
| | | |
| Exhibit No. | | Description |
| | | |
| 99.1 | | Press release of OncoGenex Pharmaceuticals, Inc. dated September 22, 2010. |
4
